Login

Switch On Your HIV Smarts.

Author Archives: Liz Highleyman

Surprising price break for newly-approved hepatitis C drug

Surprising price break for newly-approved hepatitis C drug

, by Liz Highleyman

Two new hepatitis C cure drugs, Mavyret and Vosevi, have been approved by the FDA—offering a shorter course of treatment, for a lower cost. Read More

Long-acting antiretrovirals for HIV treatment and PrEP

Long-acting antiretrovirals for HIV treatment and PrEP

, by Liz Highleyman

At the recent IAS 2017 conference, we got good news about the safety and efficacy of a long-acting antiretroviral injection and a drug in a new class of medications. Read More

In a class of its own, “uniquely potent” HIV capsid inhibitor thwarts HIV replication

In a class of its own, “uniquely potent” HIV capsid inhibitor thwarts HIV replication

, by Liz Highleyman

Promising research about a new type of HIV drug called GS-CA1, the first capsid inhibitor to enter clinical trials, was shared at CROI 2017. Read More

Antibody therapies effective at preventing HIV from invading CD4 cells

Antibody therapies effective at preventing HIV from invading CD4 cells

, by Liz Highleyman

Research on two new long-acting antibody therapies demonstrates success at protecting CD4 cells and suppressing viral loads in people living with HIV. Read More

Two new HIV drugs, Doravirine and Bictegravir, suppress viral loads in studies and proceed to Phase 3 testing

Two new HIV drugs, Doravirine and Bictegravir, suppress viral loads in studies and proceed to Phase 3 testing

, by Liz Highleyman

Two new HIV drugs, an NNRTI and an integrase inhibitor, did well in clinical trials and are currently being tested as part of fixed-dose co-formulated pills. Read More